免疫治疗在儿童及青少年软组织肉瘤中的应用进展  

Application of immunotherapy for pediatric soft-tissue sarcomas

作　　者：王舜莹 刘百慧[1] 董瑞[1] 董岿然[1] Wang Shunying;Liu Baihui;Dong Rui;Dong Kuiran(Department of Oncologic Surgery,Children’s Hospital of Fudan University,Shanghai 201102,China)

机构地区：[1]复旦大学附属儿科医院肿瘤外科,上海201102

出　　处：《中华小儿外科杂志》2024年第6期548-558,共11页Chinese Journal of Pediatric Surgery

基　　金：国家自然科学基金(82172852);唐仲英基金会(ZSBK0070)。

摘　　要：儿童与青少年软组织肉瘤分类复杂且相对少见,高危及复发/转移性软组织肉瘤的预后较差,而传统的手术与化疗的综合治疗在改善预后方面已遇到瓶颈。免疫治疗通过激活或放大机体对肿瘤的免疫反应以控制肿瘤进展,具体方法包括免疫检查点抑制剂、单克隆抗体、肿瘤疫苗、过继细胞治疗等,有望成为软组织肉瘤治疗的新路线。本文基于历年来的临床研究结果,就免疫治疗在软组织肉瘤治疗中的研究进展进行综述。Soft-tissue sarcomas are a large group of heterogeneous malignancies in children and adolescents.Despite their relative rarities,poor outcomes of high-risk and relapsing/refractory soft-tissue sarcomas have brought a heavy healthcare burden.And multi-modal regimen of surgery and chemotherapy has failed to achieve marked improvements in survival.Immunotherapy is intended for controlling the progression of tumor through activating or magnifying immune response to tumor.Various forms of immunotherapy,including checkpoint inhibitor,monoclonal antibody,cancer vaccine and adoptive cellular therapy,are all potential options for soft-tissue sarcomas.This review summarized the outcomes of immunotherapy in recent clinical trials of soft-tissue sarcoma and provided potential perspectives for future researches.

关 键 词：软组织肉瘤 免疫治疗 横纹肌肉瘤 

分 类 号：R738.6[医药卫生—肿瘤]